EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale ( LANTERN )

Mark J Kelly, Barbara Wagner, Bryan Ceronie iD, Christine Strippel, Ann Yee Lin, Adam Handel, John Soltys, Sophie Binks, Philip A Powell, Sarosh R Irani iD

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Mark J Kelly und 9 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Encephalitis, Autoantibodies, Psychometrics. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association of British Neurologists, British Medical Association, Fulbright Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

LGI1‐antibody encephalitis (LGI1‐Ab‐E) is a common form of autoimmune encephalitis where most patients demonstrate ‘good’ clinician‐rated outcomes. However, more targeted questionnaires reveal numerous debilitating symptoms for many years. To better quantify these persistent features, we designed the L GI1‐ Ant ibody E ncephalitis R ati n g (LANTERN) scale, a quantified, disease‐specific patient‐reported outcome measure (PROM), adhering to FDA guidelines.

Methods

A participant‐driven mixed‐methods approach to develop a clinically valid questionnaire over three stages: (1) Item generation through semi‐structured interviews; (2) Repeated cognitive debriefing rounds to advance comprehensibility, relevance and comprehensiveness; (3) Psychometric survey to condense the most sensitive and valid questions. Analyses incorporated sensitivity testing with multiple internal and external validations.

Results

From 73 items across six domains (Stage 1; n = 18), a questionnaire assessing the frequency and severity of 43 symptoms (80 questions), plus nine activities of daily living (ADL), was developed through cognitive debriefing (Stage 2; n = 15). This 89‐question survey was completed (Stage 3; n = 66 patients and 32 relatives) and distilled, using exploratory factor analyses, to a three‐factor symptom‐burden questionnaire comprising 41 questions (19 symptoms and 6 ADL), separated into physical, cognitive/behavioural and ADL domains. These factors demonstrated strong internal reliability (Cronbach alpha: 0.85–0.91), correlations with relative‐completed questionnaires ( R = 0.73–0.85; p < 0.001), good‐to‐excellent intraclass re‐testing correlations (0.81–0.98; n = 19) and strong associations with numerous predefined external measures.

Discussion

LANTERN represents a PROM for LGI1‐Ab‐E, with initial content, structural and construct validity and test–retest reliability. It can be used as a reliable, tailored, efficient and sensitive method to establish symptom burden in people with LGI1‐Ab‐E, both in clinical practice and trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresEncephalitisAutoantibodiesPsychometricsHumansFemaleMaleMiddle AgedAdultAgedIntracellular Signaling Peptides and ProteinsSurveys and QuestionnairesSeverity of Illness IndexYoung Adult

Substanzen

LGI1 protein, humanAutoantibodiesIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Department of Neurology, John Radcliffe Hospital, Oxford, UK.
  • Department of Neurology, Kantonsspital Aarau, Aarau, Switzerland.
  • Department of Neurosciences, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurology, University of South Alabama, Mobile, Alabama, USA.

ORCID-Profile: Bryan Ceronie, Sarosh R Irani

Förderung

  • Association of British Neurologists
  • British Medical Association
  • Fulbright Association
  • Wellcome Trust
  • Epilepsy Research UK
  • NIHR Oxford Biomedical Research Centre
  • Medical Research Council
  • Health Research Board (HRB)

Zitieren

APA

Kelly, M. J., Wagner, B., Ceronie, B., Strippel, C., Lin, A. Y., Handel, A., Soltys, J., Binks, S., Powell, P. A., & Irani, S. R. (2025). Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale ( LANTERN ). Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70006

Vancouver

Kelly MJ, Wagner B, Ceronie B, Strippel C, Lin AY, Handel A, et al. Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale ( LANTERN ). Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70006

BibTeX
@article{Kelly2025,
  author = {Kelly, Mark J and Wagner, Barbara and Ceronie, Bryan and Strippel, Christine and Lin, Ann Yee and Handel, Adam and Soltys, John and Binks, Sophie and Powell, Philip A and Irani, Sarosh R},
  title = {Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale ( LANTERN )},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70006}
}
Kostenlos starten →